INOVIO Announces Proposed Public Offering of its Common Stock

The proposed sale of new common shares would raise capital for INOVIO while diluting existing shareholders.

Rhea-AI Summary

INOVIO Pharmaceuticals (Nasdaq: INO) plans to sell shares of its common stock through an underwritten public offering, subject to market conditions.

All shares in the proposed offering will be sold by INOVIO. The company intends to grant underwriters a 30-day option to purchase additional shares totaling up to 15% of the shares offered, on the same terms and conditions. Jefferies and Piper Sandler are joint book-running managers. Whether or when the offering will be completed, and its actual size and terms, remain uncertain.

1 point · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.The proposed public offering would raise capital through common shares sold by INOVIO.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.New common shares in the proposed offering would dilute existing shareholders.
• Minor point. Forward-looking: it has not happened yet and may not happen.The planned 30-day underwriter option for up to 15% additional shares would allow further dilution.
• Minor pointOffering completion is subject to market conditions; timing, size and terms remain uncertain.

News Explained

If completed, the share sale would reduce existing holders’ ownership percentages; the effective shelf alone does not mean shares have been sold.

If completed, the sale of additional INOVIO common shares would increase the share count and reduce existing holders’ percentage ownership.

The shelf registration became effective on July 10, 2026; it authorizes future registered sales but is not itself a sale, and the company says it will file a preliminary prospectus supplement describing this offering’s terms.

Argus 15 min delay 54 alerts

-15.21% vs previous close $1.23 last price 3.9x rel. volume Open Argus

Details

Market Reaction – INO

-18.8% Trough in 17 min

$0.88 – $1.63 Day Range

$127.12M Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for INO is 15.21% below the previous close. Argus tracked a trough of -18.8% from its starting point during tracking. Our momentum scanner has recorded 54 alerts for this stock so far that day. The latest delayed price is $1.23. Relative volume is very high at 3.9x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Underwriter option: Up to 15%

Underwriter option

Up to 15%

30-day option to purchase additional offered shares on the same terms

Previous Offering Reports

1 past event · Latest: Jul 29

Same Type 1 event

1. Jul 29

   Public offering

   24h Move

   -36.9%

   INOVIO priced a $20.0 million common-share and warrant offering after a proposal.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

shelf registration statement, prospectus supplement, joint book-running managers

3 terms

shelf registration statement financial

"A shelf registration statement relating to the shares of common stock offered"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

joint book-running managers financial

"are acting as joint book-running managers for the offering"

Joint book-running managers are the lead banks or financial firms responsible for organizing and overseeing the sale of a large financial offering, such as a company’s stock or bonds. They coordinate efforts to set the price, attract investors, and ensure the offering is successful. Their role is important to investors because they help ensure the offering is well-managed, properly priced, and accessible to a wide range of buyers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. INOVIO intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares of its common stock offered in the public offering under the same terms and conditions. All of the shares in the proposed offering will be sold by INOVIO. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Jefferies and Piper Sandler are acting as joint book-running managers for the offering.

A shelf registration statement relating to the shares of common stock offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on July 2, 2026 and declared effective by the SEC on July 10, 2026. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.  

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.

Forward-Looking Statements

This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding INOVIO's anticipated public offering, including the completion of the public offering on the anticipated terms, if at all, and INOVIO's plans to grant the underwriters a 30-day option to purchase additional shares. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Contacts

Media: Josephine Galatioto - ICR Healthcare, inoviopr@icrhealthcare.com

Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, peter.vozzo@icrhealthcare.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-announces-proposed-public-offering-of-its-common-stock-302931327.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What public offering is INOVIO (INO) proposing?

INOVIO plans an underwritten public offering of common stock, with all offered shares sold by the company. The proposed offering is subject to market conditions, and its completion, timing, size and terms remain uncertain.

What additional-share option does INOVIO plan to give the offering's underwriters?

INOVIO intends to grant underwriters a 30-day option to purchase additional common shares totaling up to 15% of the shares offered in the public offering. These additional shares would carry the same terms and conditions.